Return to homepagePandemic Pact

Role of the gut in SARS-CoV-2 infection and susceptibility: from in vitro model to human [Funder: DIM 1Health]

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • start year

    -99

  • Known Financial Commitments (USD)

    $0

  • Funder

    Other Funders (France)

  • Principal Investigator

    Harry Sokol

  • Research Location

    France

  • Lead Research Institution

    N/A

  • Research Priority Alignment

    N/A

  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Disease pathogenesis

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

There is ample evidence to suggest that the gastrointestinal tract is being targeted by the novel coronavirus (SARS-CoV-2). The presence, in a significant number of cases, of digestive manifestations could even be a factor of severity of the infection. In addition, an axis of communication between the intestine and the lungs is clearly established with a strong influence of the intestinal microbiota on the susceptibility to pulmonary infections. The objectives of the COVI-Biome study are: to determine whether there are alterations in the composition and functions of the gut microbiota in patients with SARS-CoV2 infection, to look for predictive factors of severity among gastrointestinal and microbiota parameters and understand the interactions between the virus, gut cells and the microbiota.